Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Jun 2018
- Primary completion
- Jan 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab in B cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 5 more, sponsored by Genmab. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 7.5 years and 2 more. Started Jun 2018; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
B cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT03625037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625037.